Breaking Medical Technology
News: Aethlon Medical (NASDAQ: $AEMD) Prepares for Potentially Transformative
Phase 1 Cancer Treatment Studies
Phase 1 Clinical Trials of the Hemopurifier®
Designed to Include Patients With Solid Tumors Who Have Stable or Progressive
Disease During Anti-PD-1 Monotherapy Treatment, Such as Keytruda® of Opdivo®
Interested Clinical Sites Have Initiated
Submissions For Ethics Committee Review
SAN DIEGO, CA - June 3, 2024
(Investorideas.com Newswire) Aethlon Medical, Inc. (Nasdaq: AEMD), a
medical therapeutic company focused on developing products to treat cancer and
life-threatening infectious diseases, today provided the following update on
its planned phase 1 safety, feasibility and dose-finding clinical trials of its
Hemopurifier® in patients with solid tumors who have stable or progressive
disease during anti-PD-1 monotherapy treatment, such as Keytruda® or Opdivo®.
This news
is paid advertisement/ news disseminated on behalf of/issued on behalf of
Aethlon Medical Inc.
Read this news, featuring
AEMD in full at https://www.investorideas.com/news/2024/06031AEMD-Phase-1-Cancer-Treatment-Studies.asp
"We
continue to make progress preparing for our planned, safety, feasibility and
"dose finding" oncology trials in Australia and India, and want to
provide our shareholders and other constituents with an update, stated Steven
LaRosa, MD, Chief Medical Officer of Aethlon Medical. In early May, we
announced new data showing the in vitro removal of exosomes from cancer patient
plasma using a miniature version of our Hemopurifier®. This data has been
quickly integrated into the required documentation for Ethics Committees at our
potential clinical sites. On May 17, 2024, we provided these documents to the
Contract Research Organizations for these planned clinical trials.
Subsequently, on May 24, 2024, one potential site submitted the documents to
its Ethics Board. An additional site in Australia and another in India are
currently assembling the packages for submission to their Ethics Committees.
Once we receive the expected Ethics Committee approvals, we will
finalize the Clinical Trial Agreements. After this, hospitals can begin
recruiting patients for the trials.
As a
reminder, the target patient population for these safety, feasibility, and dose
finding trials is oncology patients with solid tumors who are failing their
anti-PD-1 monotherapy treatment, such as Keytruda® or Opdivo®.
About Aethlon and the
Hemopurifier®
Aethlon Medical is a medical therapeutic company focused on
developing the Hemopurifier, a clinical stage immunotherapeutic device which is
designed to combat cancer and life-threatening viral infections and for use in
organ transplantation. In human studies, the Hemopurifier has demonstrated the
removal of life-threatening viruses and in pre-clinical studies, the
Hemopurifier has demonstrated the removal of harmful exosomes from biological
fluids, utilizing its proprietary lectin-based technology. This action has
potential applications in cancer, where exosomes may promote immune suppression
and metastasis, and in life-threatening infectious diseases. The Hemopurifier
is a U.S. Food and Drug Administration (FDA) designated Breakthrough Device
indicated for the treatment of individuals with advanced or metastatic cancer
who are either unresponsive to or intolerant of standard of care therapy, and
with cancer types in which exosomes have been shown to participate in the
development or severity of the disease. The Hemopurifier also holds an FDA
Breakthrough Device designation and an open Investigational Device Exemption
(IDE) application related to the treatment of life-threatening viruses that are
not addressed with approved therapies.
Additional information can be found at www.AethlonMedical.com.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934 that involve risks and uncertainties.
Statements containing words such as "may," "believe,"
"anticipate," "expect," "intend," "plan,"
"project," "will," "projections," "estimate,"
"potentially" or similar expressions constitute forward-looking
statements. Such forward-looking statements are subject to significant risks
and uncertainties and actual results may differ materially from the results
anticipated in the forward-looking statements. These forward-looking statements
are based upon Aethlon's current expectations and involve assumptions that may
never materialize or may prove to be incorrect. Factors that may contribute to
such differences include, without limitation, the Company's ability to
successfully raise additional capital and to complete development of the
Hemopurifier and to successfully demonstrate the utility of the Hemopurifier in
cancer and infectious diseases; the Company's ability to demonstrate synergies
of the Hemopurifier with the NucleoCapture and HemoNucleoCapture devices; the
Company's ability to enter into a future collaboration with Santersus; the
Company's ability to complete the internal binding study of relevant
extracellular vesicles; the Company's ability to commence and manage its
clinical trials; and other potential risks. The foregoing list of risks and
uncertainties is illustrative, but is not exhaustive. Additional factors that
could cause results to differ materially from those anticipated in forward-looking
statements can be found under the caption "Risk Factors" in the
Company's Annual Report on Form 10-K for the year ended March 31, 2023, and in
the Company's other filings with the Securities and Exchange Commission,
including its quarterly Reports on Form 10-Q. All forward-looking statements
contained in this press release speak only as of the date on which they were
made. Except as may be required by law, the Company does not intend, nor does
it undertake any duty, to update this information to reflect future events or
circumstances.
Company Contact:
Jim Frakes
Interim Chief Executive Officer and Chief Financial Officer
Aethlon Medical, Inc.
Jfrakes@aethlonmedical.com
Investor Contact:
Susan Noonan
S.A. Noonan Communications, LLC
susan@sanoonan.com
917-513-5303
Aethlon
Medical Inc. (Nasdaq:AEMD) is a featured biotech stock on Investorideas.com
More info on AEMD at Investorideas.com Visit: https://www.investorideas.com/CO/AEMD/
Get News
Alerts on Aethlon Medical
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced
news, articles and equity research as well as creates original content,
including video, interviews and articles. Original content created by
investorideas is protected by copyright laws other than syndication rights. Our
site does not make recommendations for purchases or sale of stocks, services or
products. Nothing on our sites should be construed as an offer or solicitation
to buy or sell products or securities. All investing involves risk and possible
losses. This site is currently compensated for news publication and
distribution, social media and marketing, content creation and more. Disclosure
is posted for each compensated news release, content published /created if
required but otherwise the news was not compensated for and was published for
the sole interest of our readers and followers. Contact management and IR of
each company directly regarding specific questions. Disclosure: Aethlon
Medical, Inc. (NASDAQ:AEMD) is a paid featured stock on Investorideas.com More
disclaimer info: https://www.investorideas.com/About/News/Clientspecifics.asp https://www.investorideas.com/About/Disclaimer.asp
Learn more about publishing your news release and
our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ Global investors must adhere to regulations of
each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Biotech Industry Stocks- investing ideas
in biotechnology stocks, medical technology and life sciences
Like Biotech Stocks? View our Biotech Stocks Directory
Get News Alerts on Biotech Stocks
